Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Generation Bio Co. - Common stock (GBIO)
Company Research
Source: GlobeNewswire
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. “Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a long-standing challenge for siRNA therapeutics, which is to reach T cells while sparing broader immune cells and achieve potent knockdown of genetic targets in vivo,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “Significant classes of drugs in immune and inflammation indi
Show less
Read more
Impact Snapshot
Event Time:
GBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GBIO alerts
High impacting Generation Bio Co. - Common stock news events
Weekly update
A roundup of the hottest topics
GBIO
News
- Generation Bio Co. (NASDAQ: GBIO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial ResultsGlobeNewswire
- Generation Bio Co. (NASDAQ: GBIO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Generation Bio to Present at the Needham 24th Annual Virtual Healthcare ConferenceGlobeNewswire
GBIO
Earnings
- 5/7/25 - Beat
GBIO
Sec Filings
- 5/7/25 - Form S-8
- 5/7/25 - Form 10-Q
- 5/7/25 - Form 8-K
- GBIO's page on the SEC website